current
licens
vaccin
prevent
pathogenesi
around
virus
bacteria
nevertheless
still
import
challeng
area
includ
develop
activ
noninvas
thermoresist
vaccin
import
biotechnolog
advanc
led
safer
subunit
antigen
protein
peptid
nucleic
acid
howev
limit
immunogen
demand
potent
adjuv
strengthen
immun
respons
particul
nanocarri
hold
high
potenti
adjuv
vaccin
due
pathogenlik
size
structur
enhanc
immun
respons
mimick
natur
infect
process
addit
tailor
noninvas
mucos
administr
needlefre
vaccin
control
deliveri
associ
antigen
specif
locat
prolong
time
open
room
singledos
vaccin
moreov
allow
coassoci
immunostimulatori
molecul
improv
overal
adjuv
capac
natur
ubiquit
charact
polysaccharid
togeth
intrins
immunomodul
properti
biocompat
biodegrad
justifi
interest
engin
nanovaccin
review
aim
provid
stateoftheart
overview
regard
applic
nanotechnolog
vaccin
deliveri
focu
recent
advanc
develop
applic
polysaccharidebas
antigen
nanocarri
throughout
last
decad
vaccin
play
fundament
role
prevent
sever
infecti
diseas
even
erad
despit
advanc
achiev
date
signific
challeng
still
need
face
order
gradual
increas
vaccin
coverag
includ
develop
new
vaccin
certain
pathogen
human
immunodefici
viru
hiv
malaria
tuberculosi
among
other
also
develop
singledos
needlefre
vaccin
intend
improv
patient
complianc
reduc
associ
cost
lastli
product
formul
avoid
cold
chain
transport
repres
keyston
improv
vaccin
worldwid
progress
antigen
adjuv
develop
led
recognit
valu
nanotechnolog
deal
indic
challeng
prepar
nanovaccin
differ
immunomodul
biomateri
propos
includ
polysaccharid
innov
approach
main
focu
review
summar
fig
fig
advanc
biolog
microbiolog
technolog
increas
knowledg
pathogen
led
develop
newer
safer
subunit
antigen
nevertheless
antigen
less
effect
induc
protect
immun
respons
therefor
requir
parallel
develop
potent
adjuv
immunomodul
molecul
particul
deliveri
system
among
polysaccharidebas
nanosystem
demonstr
potenti
success
use
vaccin
formul
first
commercialis
vaccin
rabi
poliomyel
tetanu
childhood
tuberculosi
among
other
base
attenu
pathogen
toxin
howev
potenti
toxic
difficulti
carri
process
complex
pathogen
hiv
hepat
c
viru
hcv
led
search
optimis
antigen
delani
et
al
advanc
biotechnolog
increas
knowledg
pathogen
characterist
led
develop
newer
safer
subunit
antigen
particular
protein
peptid
nucleic
acid
nabel
recombin
dna
technolog
allow
product
sever
protein
antigen
activ
use
express
vector
bacteria
yeast
wellknown
exampl
applic
product
hepat
b
surfac
antigen
rhbsag
escherichia
coli
led
first
recombin
proteinbas
vaccin
reach
market
use
alum
adjuv
glaxosmithklin
biolog
recombivax
merck
co
inc
similarli
antigen
human
papillomaviru
hpv
express
saccharomyc
cerevisa
trichoplusia
ni
commercialis
merck
co
inc
glaxosmithklin
biolog
alum
combin
alum
monophosphoryl
lipid
mpla
adjuv
respect
pathogen
recombin
protein
antigen
identifi
studi
includ
hepat
c
e
rotaviru
ohtak
arakawa
concept
revers
vaccinolog
focuss
scan
whole
genom
pathogen
identif
antigen
protein
candid
repres
import
advanc
toward
develop
new
vaccin
strategi
led
develop
exampl
new
meningococc
vaccin
commercialis
europ
brand
name
novarti
vaccin
vaccin
pathogen
streptococcu
pneumonia
leishmania
infantum
among
other
also
investig
use
approach
donati
rappuoli
indic
antigen
protein
still
import
limit
complex
product
process
difficult
purif
step
instabl
liquid
form
importantli
proteinbas
vaccin
may
induc
autoimmun
allerg
reaction
report
exampl
develop
vaccin
group
streptococcu
ga
batzloff
et
al
skwarczynski
toth
reason
effort
current
focuss
product
small
peptid
antigen
antigen
peptid
identifi
analysi
specif
antibodyinduc
region
within
larger
protein
epitop
gener
obtain
simpl
synthesi
high
puriti
larg
scale
lower
cost
gori
et
al
purcel
et
al
rosendahl
huber
et
al
skwarczynski
toth
sever
peptidebas
vaccin
formul
alreadi
reach
clinic
develop
phase
case
prevent
hiv
vaccin
girard
et
al
well
therapeut
anticanc
vaccin
mohit
et
al
ott
et
al
overal
state
protein
peptid
improv
vaccin
safeti
profil
comparison
live
attenu
pathogen
howev
poor
immunogen
definit
hinder
develop
success
gori
et
al
purcel
et
al
reason
essenti
advanc
design
novel
adjuv
may
help
provid
vaccin
robust
immun
respons
fox
et
al
last
decad
nucleic
acidbas
vaccin
gain
increas
attent
deer
et
al
xiang
et
al
essenti
nucleic
acid
plasmid
dna
pdna
messeng
rna
mrna
allow
situ
product
antigen
cellular
machineri
host
strategi
mimic
natur
infect
intracellular
pathogen
lead
local
format
antigen
molecul
moreov
nucleic
acid
tailor
express
antigen
chemic
structur
differ
nativ
form
intent
improv
immunogen
alpar
et
al
deer
et
al
kramp
probst
main
limit
approach
low
level
gene
express
achiev
upon
administr
limit
overcom
design
effect
viral
nonvir
transfect
vector
alpar
et
al
mazid
et
al
plasmid
dna
vaccin
base
administr
select
antigenencod
dna
plasmid
vector
appli
prevent
diseas
malaria
hiv
also
therapeut
approach
cancer
immunotherapi
formul
alreadi
reach
clinic
develop
phase
recent
review
mazid
et
al
liu
mazid
et
al
nevertheless
risk
genom
integr
longterm
effect
vaccin
yet
clarifi
schalk
et
al
altern
messeng
rna
rais
particular
attent
preclin
proofsofconcept
describ
prophylact
influenza
vaccin
formul
clinic
develop
anticanc
immunotherapi
deer
et
al
kramp
probst
alum
tradit
adjuv
choic
vaccin
though
mechan
action
yet
complet
understood
also
specif
limit
necess
store
low
temperatur
limit
efficaci
peptid
antigen
inabl
gener
cellular
immun
respons
azmi
et
al
bomford
lindblad
need
overcom
limit
stimul
search
new
adjuv
consequ
current
larg
varieti
adjuv
purpos
review
classifi
two
group
molecular
adjuv
immunostimulatori
molecul
antigen
deliveri
system
produc
nanoengin
antigen
small
molecul
target
specif
receptor
present
immun
cell
pattern
recognit
receptor
prr
tolllik
receptor
tlr
abil
trigger
stronger
immun
respons
demento
et
al
studi
molecul
agonist
tlr
exampl
cpg
oligonucleotid
tlr
poli
c
tlr
imiquimod
tlr
alreadi
evalu
adjuv
properti
vaccin
malaria
hepat
b
influenza
well
differ
therapeut
anticanc
vaccin
steinhagen
et
al
molecul
bacteri
toxin
cholera
toxin
e
coli
heatlabil
toxin
other
saponin
quila
cytokin
also
use
immunostimul
vaccin
formul
particular
bacteri
toxin
known
enhanc
immun
respons
target
antigen
cell
intestin
tract
therebi
boost
strong
humor
respons
mucos
level
exampl
toxin
cholera
toxin
recombin
b
subunit
use
adjuv
commerci
oral
cholera
vaccin
hill
et
al
anoth
exampl
refer
transderm
patch
contain
heatlabil
e
coli
enterotoxin
enhanc
immun
respons
pathogen
e
coli
influenza
behren
et
al
frech
et
al
glenn
et
al
nevertheless
major
limit
toxin
relat
immun
respons
gener
rather
associ
antigen
mallapragada
narasimhan
reed
et
al
wilsonweld
et
al
case
saponin
plantderiv
triterpen
glycosid
detoxifi
deriv
quila
quillaja
saponaria
success
includ
particul
formul
liposom
base
monophosphoryl
lipid
mpla
squalen
oilinwat
emuls
also
contain
mpla
current
clinic
develop
malaria
vaccin
kester
et
al
rtss
clinic
trial
partnership
also
inclus
saponin
immunostimul
complex
iscom
evalu
vaccin
influenza
toxoplasmosi
epsteinbarr
virusinduc
tumour
among
other
achiev
protect
immun
clinic
studi
barr
et
al
sun
et
al
respect
cytokin
molecul
studi
immun
respons
modul
preclin
clinic
level
though
toxic
effect
observ
high
dose
human
studi
hedlund
et
al
hugh
lynch
et
al
macromolecul
polym
among
polysaccharid
review
section
lipid
mpla
squalen
well
sever
phospholipid
also
use
case
nanoengin
antigen
lead
format
nanocarri
antigen
deliveri
system
fox
perrincocon
et
al
specif
moieti
pathogenassoci
molecular
pattern
pamp
recogn
prr
occas
natur
present
macromolecul
synthet
includ
structur
potenti
function
demento
et
al
morasolano
collier
case
mpla
squalen
recogn
immunomodul
featur
led
inclus
market
vaccin
compon
approv
adjuv
case
squalen
case
mpla
well
formul
still
preclin
clinic
develop
rappuoli
et
al
nanoengin
approach
use
associ
antigen
deliveri
carrier
made
specif
biomateri
normal
recogn
adjuv
properti
deliveri
carrier
abl
transport
control
releas
antigen
cell
exert
biolog
activ
polymer
nanoparticl
iscom
liposom
lipid
nanoparticl
among
other
includ
categori
azmi
et
al
correiapinto
et
al
et
al
sahdev
et
al
gener
recogn
depot
effect
gener
major
antigen
deliveri
system
subcutan
inject
allow
uptak
antigen
present
cell
attract
featur
type
adjuv
aguilar
bachmann
jen
moreov
abl
mimic
particul
natur
pathogen
therefor
increas
possibl
effect
immun
respons
de
temmerman
et
al
context
nanotechnolog
expect
signific
impact
discuss
follow
section
use
technolog
biomateri
nanometr
scale
therapeut
diagnost
grow
research
field
sinc
second
half
centuri
duncan
gaspar
larg
varieti
nanoparticul
system
develop
throughout
past
decad
improv
deliveri
target
efficaci
drug
biomolecul
nucleic
acid
antigen
etheridg
et
al
depend
compon
methodolog
chosen
possibl
develop
wide
rang
nanostructur
exampl
polymer
nanoparticl
base
matrixtyp
entangl
select
polym
ii
oilinwat
ow
nanoemuls
consist
oil
nanodrop
stabil
adequ
surfact
iii
nanocapsul
polymerco
nanoemuls
form
coreshel
nanostructur
iv
lipidbas
nanosystem
liposom
solid
lipid
nanoparticl
among
other
area
vaccin
nanotechnolog
led
develop
nanostructur
hold
specif
advantag
antigen
deliveri
first
mention
due
particul
structur
nanometr
size
similar
one
viru
bacteria
nanoparticl
mimic
natur
infect
process
takenup
antigen
present
cell
apc
therebi
lead
enhanc
immun
respons
bachmann
jen
reddi
et
al
storni
et
al
zolnik
et
al
number
author
report
particl
nanometr
rang
particularli
suitabl
interact
immun
system
fifi
et
al
joshi
et
al
reddi
et
al
addit
lab
work
plapeg
micro
nanoparticl
also
observ
nmnanoparticl
enhanc
transport
antigen
nasal
mucosa
effici
microparticl
either
intranas
administr
vila
et
al
howev
still
controversi
regard
issu
work
support
idea
microparticl
elicit
stronger
immun
respons
gutierro
et
al
kanchan
panda
disagr
may
come
difficulti
compar
differ
studi
mani
variabl
account
total
outcom
immun
respons
constitut
biomateri
natur
dose
antigen
rout
administr
oyewumi
et
al
also
hypothes
use
nanoparticl
may
favour
cellular
immun
respons
optim
interact
dendrit
cell
dc
subset
bachmann
jen
exampl
use
model
carboxil
polystyren
micro
nanoparticl
nm
load
ovalbumin
ova
fifi
et
al
shown
nanoparticl
abl
elicit
significantli
higher
igg
tcell
respons
final
report
size
nm
desir
purpos
facilit
transport
nanoparticl
subcutan
tissu
lymph
node
antigen
present
matur
immun
cell
adapt
immun
respons
reddi
et
al
reddi
et
al
nanostructur
also
shown
interest
potenti
mucos
antigen
deliveri
due
abil
interact
get
across
mucos
barrier
csaba
et
al
de
rieux
et
al
properti
mainli
relat
particl
size
desai
et
al
jani
et
al
also
composit
favour
system
includ
mucoadhes
materi
chitosan
grabovac
et
al
moreov
group
pioneer
demonstr
modif
nanocarri
polyethylen
glycol
peg
unit
differ
degre
also
respons
improv
transport
system
across
nasal
mucosa
overal
increas
interact
system
mucosa
boost
antigen
present
area
natur
entranc
sever
pathogen
usual
happen
therefor
mimick
natur
infect
process
mucos
antigen
deliveri
needlefre
vaccin
allow
overcom
import
limit
associ
parenter
immun
high
cost
prepar
need
specif
administr
materi
needl
syring
special
technic
staff
also
like
well
accept
patient
altogeth
result
improv
vaccin
coverag
chadwick
et
al
giudic
campbel
final
anoth
import
advantag
nanosystem
vaccin
deliveri
possibl
coencapsul
addit
immunostimulatori
molecul
one
describ
section
purpos
increas
overal
adjuv
capac
exampl
tlr
agonist
cpg
poli
c
imiquimod
vicent
et
al
associ
dextran
nanoparticl
chitosan
nanocapsul
respect
molecul
promot
specif
receptorbas
recognit
nanovaccin
consequ
cell
activ
strengthen
elicit
immun
respons
highlight
potenti
nanoparticl
vaccin
worth
mention
formul
alreadi
reach
market
other
advanc
clinic
stage
develop
nanoemuls
oilinwat
nanoemuls
contain
squalen
roman
et
al
also
squalen
oilinwat
nanoemuls
stabil
esposito
et
al
commerci
influenza
vaccin
name
glaxosmithklin
biolog
novarti
respect
virosom
compos
phospholipid
membran
incorpor
viral
glycoprotein
present
commerci
hepat
influenza
vaccin
crucel
respect
usoni
et
al
nanometr
formul
liposom
base
mpla
lerouxroel
et
al
squalen
oilinwat
emuls
also
contain
mpla
aid
et
al
one
polymer
carrier
base
plga
among
other
current
clinic
develop
differ
vaccin
describ
tabl
consid
clear
nanometr
deliveri
system
spotlight
potenti
vaccin
late
work
kreuter
speiser
open
way
specif
use
polym
polymethylmethacryl
materi
engin
antigen
nanocarri
kreuter
speiser
sinc
signific
number
studi
put
evid
potenti
nanoparticl
enhanc
immun
respons
differ
antigen
sustain
prolong
way
correiapinto
et
al
et
al
reddi
et
al
riceficht
et
al
vicent
et
al
group
particularli
activ
field
pioneer
encapsul
model
protein
antigen
within
poli
lacticcoglycol
acid
plga
blanco
alonso
polylact
acidpolyethylen
glycol
plapeg
nanoparticl
interestingli
work
follow
great
number
author
danhier
et
al
whose
contribut
led
clinic
develop
plgabas
nanovaccin
wwwclinicaltrialsgov
along
engin
trajectori
becam
clear
major
inconveni
biomateri
degrad
antigen
encapsul
cours
polym
degrad
alonso
et
al
although
specif
formul
strategi
found
significantli
reduc
effect
encapsul
antigen
et
al
schwendeman
et
al
overal
result
achiev
use
plgabas
nanoengin
persuad
us
other
search
new
biomateri
might
mild
interact
antigen
natur
occur
polym
particular
polysaccharid
attract
attent
mid
biomateri
antigen
nanoengin
goal
mind
report
first
time
product
nanoparticl
consist
assembl
protein
chitosan
calvo
et
al
describ
follow
section
follow
author
propos
use
polysaccharid
ie
dextran
mannan
beta
glucan
nanoengin
vaccin
petrovski
cooper
latter
biomateri
found
cell
wall
sever
pathogen
bacteria
yeast
characterist
provid
intrins
target
abil
apc
act
pamp
prr
present
cell
consequ
natur
capac
enhanc
immun
respons
associ
antigen
demento
et
al
dykstra
et
al
morasolano
collier
petrovski
cooper
import
featur
high
biocompat
low
toxic
make
polysaccharid
particularli
interest
pharmaceut
develop
purpos
anoth
specif
advantag
associ
use
polysaccharidebas
antigen
nanocarri
relat
technolog
use
produc
technolog
reli
physicochem
process
ionic
gelat
calvo
et
al
complex
kean
et
al
solvent
displac
calvo
et
al
among
other
gener
simpl
mild
techniqu
minim
use
solvent
highenergi
sourc
easi
scaleup
importantli
suitabl
associ
labil
biomolecul
vauthier
bouchem
apart
select
appropri
technolog
relev
technic
aspect
develop
nanovaccin
ie
stabil
antigen
term
biolog
activ
stabil
formul
storag
consid
earli
stage
develop
amorij
et
al
chen
zehrung
select
raw
materi
pharmaceut
qualiti
ie
produc
accord
specif
criteria
assur
high
puriti
adequ
characterist
use
human
good
interbatch
reproduc
also
import
topic
take
consider
process
nanovaccin
design
manufactur
nevertheless
potenti
biomateri
field
deserv
deeper
analysi
publish
materi
concern
polysaccharidebas
nanosystem
vaccin
reason
characterist
main
polysaccharid
describ
adjuv
properti
well
applic
develop
nanovaccin
detail
follow
chitosan
cs
natur
occur
polym
compos
linear
backbon
dglucosamin
nacetyldglucosamin
monom
connect
bond
polysaccharid
mainli
obtain
deacetyl
chitin
present
exoskeleton
crustacean
squid
though
sourc
fungi
also
report
gome
et
al
one
relev
characterist
chitosan
possibl
modul
degre
acetyl
therefor
number
amino
group
gome
et
al
cation
charact
allow
electrostat
interact
antigen
neg
charg
physiolog
condit
also
respons
abil
interact
mucos
surfac
islam
et
al
sogia
et
al
author
indic
potenti
chitosan
immunomodulatori
properti
base
vitro
vivo
studi
perform
use
chitosan
solut
precis
peluso
et
al
found
chitosan
solut
activ
periton
rat
macrophag
enhanc
nitric
oxid
secret
vitro
peluso
et
al
hand
porporatto
et
al
report
abil
chitosan
trigger
local
system
immun
respons
evidenc
enhanc
cytokin
product
upon
oral
administr
singl
mg
dose
polysaccharid
solut
rat
porporatto
et
al
final
zaharoff
et
al
evalu
adjuv
potenti
chitosan
solut
mg
dose
given
subcutan
comparison
phosphat
buffer
salin
solut
pb
common
adjuv
alum
incomplet
freund
adjuv
ifa
use
model
protein
antigen
zaharoff
et
al
result
shown
abil
chitosan
induc
humor
cellular
respons
superior
nonadjuv
formul
alumadjuv
one
equival
one
achiev
use
ifa
nevertheless
immunomodulatori
properti
still
question
could
relat
uncontrol
precipit
chitosan
physiolog
ph
also
sourc
qualiti
chitosan
use
respect
biocompat
biodegrad
chitosan
worth
mention
chitosan
gener
recogn
safe
gra
statu
grant
unit
state
food
drug
administr
fda
chitosan
use
long
time
dietari
supplement
prevent
fat
absorpt
compon
wound
dress
boateng
et
al
hand
chitosan
present
new
nasal
vaccin
formul
mening
noroviru
clinic
develop
atmar
et
al
huo
et
al
addit
present
vaccin
hydrogel
formul
influenza
intramuscular
inject
neimertandersson
et
al
overal
chitosan
therefor
consid
one
advanc
polym
regulatori
path
indic
vaccin
take
account
also
preclin
evid
potenti
chitosanbas
nanocarri
adjuv
mucos
parenter
immun
tabl
could
expect
chitosan
nanoformul
could
enter
clinic
trial
oncom
year
protein
nanovaccin
parenter
vaccin
chitosanbas
nanovaccin
indic
chitosan
nanoparticl
develop
first
time
calvo
et
al
wide
studi
deliveri
protein
antigen
arca
et
al
exampl
chitosan
nanoparticl
associ
rhbsag
exhibit
adjuv
effect
higher
alum
intramuscular
administr
mice
prego
et
al
studi
address
coassoci
immunostimul
molecul
ie
cpg
rhbsag
chitosan
nanoparticl
vaccin
formul
increas
igg
titr
comparison
antigen
solut
upon
subcutan
administr
mice
borg
et
al
chitosan
nanoparticl
addit
report
potenti
singledos
vaccin
strategi
rhbsag
lugad
et
al
result
studi
indic
singl
intraperiton
intramuscular
subcutan
inject
nanoparticl
respons
achiev
stronger
last
longer
one
elicit
singl
dose
recombivax
alumassoci
rhbsag
given
intraperiton
differ
type
chitosanbas
nanocarri
ie
chitosan
nanocapsul
origin
disclos
group
prego
et
al
similarli
propos
singledos
immun
schedul
rhbsag
vicent
et
al
addit
develop
freezedri
formul
order
improv
preserv
vaccin
result
observ
upon
singl
intramuscular
administr
mice
indic
igg
level
compar
obtain
vaccin
alumadsorb
antigen
primeboost
scheme
week
could
also
prove
nanocapsul
adequ
coencapsul
tlr
imiquimod
vicent
et
al
formul
approach
nasal
immun
discuss
next
section
recent
conduct
experi
assess
biodistribut
nanocapsul
subcutan
inject
vicent
et
al
result
evidenc
format
depot
follow
slow
drainag
nanocapsul
toward
lymph
node
accumul
illustr
see
fig
result
allow
us
conclud
biodistribut
profil
respons
longlast
adjuv
effect
observ
chitosan
nanocapsul
mucos
vaccin
chitosanbas
nanovaccin
apart
promis
result
obtain
parenter
immun
use
chitosan
nanovaccin
great
deal
effort
address
develop
chitosanbas
nanovaccin
intend
mucos
vaccin
group
pioneer
develop
first
chitosanbas
nanovaccin
needlefre
vaccin
strategi
vila
et
al
result
show
intranas
administr
mice
chitosanbas
tetanu
toxoid
tt
nanovaccin
led
high
longlast
igg
level
compar
elicit
alumadsorb
vaccin
administ
intramuscularli
vila
et
al
recent
chitosan
nanoparticl
studi
associ
hemagglutinin
protein
influenza
viru
intranas
administr
hemagglutininload
chitosan
nanoparticl
mice
system
mucos
antibodi
level
igg
iga
significantli
enhanc
respect
control
antigen
solut
cell
respons
also
report
importantli
challeng
rout
viru
anim
receiv
nanovaccin
present
higher
surviv
rate
sawaengsak
et
al
anoth
studi
chitosan
nanoparticl
load
streptococcu
equi
bacteri
protein
administ
intranas
mice
result
show
enhanc
igg
iga
respons
compar
elicit
antigenload
liposom
correspond
empti
nanoparticl
liposom
figueiredo
et
al
group
also
explor
potenti
coencapsul
rhbsag
immunostimul
imiquimod
chitosan
nanocapsul
enhanc
immun
respons
follow
intranas
vaccin
vicent
et
al
result
obtain
mice
evidenc
enhanc
specif
balanc
immun
respons
significantli
higher
one
observ
rhbsagload
chitosan
nanocapsul
without
imiquimod
control
rhbsagload
nanoemuls
fig
result
highlight
posit
effect
codeliv
addit
immunostimul
molecul
antigen
singl
nanostructur
open
room
potenti
modul
immun
toward
cellular
pathway
use
needlefre
vaccin
approach
chitosan
deriv
higher
water
solubl
phindepend
cation
natur
ntrimethyl
chitosan
tmc
also
evalu
prepar
nanovaccin
intraduoden
immun
ovaload
tmc
nanoparticl
mice
provid
similar
immun
respons
convent
chitosan
nanoparticl
term
igg
level
show
improv
abil
induc
dc
matur
et
al
behaviour
ovaload
tmc
nanoparticl
also
compar
ovaload
plga
ovaload
tmccoat
plga
nanoparticl
upon
intranas
intramuscular
administr
healthi
mice
formul
could
enhanc
immun
respons
follow
intramuscular
administr
tmc
nanoparticl
abl
elicit
immun
respons
intranas
administr
fact
attribut
increas
interact
nasal
mucosa
et
al
efficaci
nanoparticl
also
compar
tmcova
conjug
previous
develop
intramuscular
administr
shown
adjuv
activ
similar
tmc
nanoparticl
et
al
upon
intranas
administr
tmc
tt
igg
level
upon
dose
higher
report
antigen
solut
compar
im
alumadsorb
vaccin
nanoparticl
tt
tmc
nanoparticl
dose
elicit
similar
respons
chitosan
nanoparticl
significantli
higher
antigen
solut
hemagglutinin
two
dose
nanovaccin
elicit
high
igg
iga
level
induct
product
spleen
cell
cellular
respons
increas
surviv
challeng
anim
streptococcu
equi
higher
iga
level
increas
mucos
uptak
balanc
respons
comparison
cation
liposom
dose
ova
conjug
nm
ovaload
tmc
nanoparticl
nm
result
shown
conjug
superior
term
igg
iga
level
elicit
fact
attribut
higher
uptak
structur
nasal
epithelium
et
al
anoth
studi
ttload
tmc
nanoparticl
compar
ttload
chitosan
nanoparticl
upon
either
intranas
subcutan
administr
mice
correspond
polym
solut
control
result
evidenc
similar
behaviour
type
nanoparticl
term
igg
respons
et
al
final
tmc
also
use
combin
hyaluronan
ha
verheul
et
al
despit
observ
immun
respons
upon
intranas
administr
mice
benefit
incorpor
ha
formul
remain
unclear
sinc
compar
studi
plain
tmc
nanoparticl
includ
work
last
exampl
correspond
ovaload
tmc
nanoparticl
coencapsul
addit
immunostimul
molecul
name
lipopolysaccharid
lp
agonist
cpg
agonist
pam
csk
agonist
muramyl
dipeptid
mdp
nodlik
receptor
ligand
cholera
toxin
b
subunit
ctb
gangliosid
receptor
ligand
bal
et
al
upon
intranas
administr
healthi
mice
respons
report
case
except
cpg
highest
respons
achiev
nanoparticl
coassoci
mdp
parenter
vaccin
chitosannucl
acidbas
nanovaccin
chitosan
nanoparticl
also
develop
deliveri
plasmid
dna
immun
purpos
gome
et
al
coupl
exampl
chitosan
nanoparticl
load
plasmid
dna
encod
recombin
major
outer
membran
protein
chlamydia
trachomati
cambridg
et
al
three
tcell
epitop
mycobacterium
tuberculosi
antigen
critic
virul
feng
et
al
first
case
result
show
high
express
level
c
trachomati
protein
intramuscular
administr
mice
site
inject
also
system
ie
spleen
cambridg
et
al
second
exampl
result
obtain
intramuscular
administr
mice
indic
protect
tuberculosi
challeng
associ
strong
cytotox
lymphocyt
ctl
respons
feng
et
al
mucos
vaccin
chitosannucl
acidbas
nanovaccin
chitosan
nanoparticl
test
intranas
immun
sever
pathogen
one
exampl
refer
chitosan
nanoparticl
associ
plasmid
encod
multiepitop
protein
tuberculosi
formul
provid
administ
mice
adequ
protect
bacteri
challeng
protect
associ
signific
tcell
respons
fig
serum
igg
level
achiev
intranas
immun
two
dose
week
indic
arrow
healthi
mice
rhbsagimiquimodload
chitosan
nanocapsul
rhbsagload
chitosan
nanocapsul
without
imiquimod
rhbsagload
nanoemuls
control
group
without
chitosan
p
b
rhbsagload
chitosan
nanocapsul
without
imiquimod
rhbsagload
nanoemuls
p
b
rhbsagimiquimodload
chitosan
nanocapsul
two
formul
reproduc
permiss
vicent
et
al
ai
et
al
anoth
studi
also
tuberculosi
immun
chitosan
nanoparticl
load
plasmid
encod
antigen
togeth
second
plasmid
encod
autophagyinduc
factor
mycmtor
meerak
et
al
immun
mice
subcutan
prime
two
intranas
boost
interv
result
prove
synergist
effect
due
coadministr
plasmid
term
immun
respons
chitosan
nanoparticl
also
evalu
hepat
b
upon
associ
plasmid
encod
hepat
b
surfac
antigen
prc
cmvhb
khatri
et
al
result
show
respons
intranas
administr
mice
accompani
increas
iga
level
nasal
salivari
vagin
secret
attempt
improv
efficaci
dna
carrier
intranas
immun
chitosan
nanoparticl
load
plasmid
encod
nucleocapsid
protein
sever
acut
respiratori
syndrom
coronaviru
pvaxn
decor
bifunct
fusion
protein
bffp
target
dc
surfac
receptor
also
antibodi
bind
dc
receptor
stimul
cell
mice
immun
either
intranas
intramuscularli
nake
pvaxn
ii
pvaxnload
nanoparticl
iii
bffp
decor
pvaxnload
nanoparticl
iv
bffp
decor
pvaxnload
nanoparticl
result
indic
nanoparticl
decor
molecul
approach
effici
term
igg
iga
respons
irrespect
administr
rout
raghuwanshi
et
al
incorpor
immunostimulatori
molecul
chitosanbas
nanocarri
also
evalu
detail
heuk
et
al
heuk
borchard
heuk
et
al
graft
tlr
agonist
tmc
prepar
nanoparticl
model
plasmid
pgfp
vitro
result
show
incorpor
pam
cy
agonist
agonist
enhanc
releas
cytokin
respons
attract
leukocyt
local
infect
chitosan
nanovaccin
also
test
oral
immun
li
et
al
oliveira
et
al
interest
work
refer
associ
plasmid
dna
encod
der
allergen
hous
dust
mite
chitosan
nanoparticl
oral
administ
healthi
mice
result
evidenc
high
low
ige
level
togeth
high
low
secret
accord
reduct
allerg
respons
li
et
al
anoth
work
chitosan
deriv
contain
imidazol
moieti
csimi
use
prepar
nanoparticl
deliveri
plasmid
encod
schistosoma
mansoni
antigen
protein
oliveira
et
al
oral
administr
three
dose
pdnaload
csimi
nanoparticl
healthi
mice
week
anim
challeng
pathogen
result
evidenc
reduct
main
pathogen
effect
liver
granulomatosi
comparison
control
anim
receiv
pb
interestingli
one
control
group
receiv
blank
chitosan
nanoparticl
without
antigen
also
promot
strong
worm
burden
reduct
comparison
control
group
fact
attribut
immun
reaction
chitosan
sinc
similar
carbohydr
present
parasit
structur
chitosanco
liposom
also
describ
mucos
immun
khatri
et
al
detail
glycol
chitosanco
liposom
associ
plasmid
encod
surfac
hepat
b
antigen
prccmvhb
administ
intranas
mice
khatri
et
al
result
term
igg
respons
similar
observ
control
mice
receiv
convent
alumadsorb
encod
antigen
hbsag
intramuscularli
howev
coat
liposom
promot
superior
cell
respons
evidenc
level
moreov
iga
level
nasal
vagin
salivari
secret
detect
anim
immun
chitosanco
liposom
anoth
exampl
chitosanco
liposom
load
plasmid
encod
surfac
antigen
streptoccocu
mutan
dental
cari
prevent
efficaci
compar
plasmidload
chitosan
nanoparticl
plasmid
solut
intranas
administr
healthi
mice
chitosanco
liposom
elicit
improv
immun
respons
relat
control
antigen
releas
improv
interact
plasmidload
nanoparticl
nasal
mucosa
global
result
evid
increas
interest
chitosanbas
nanovaccin
particularli
either
parenter
mucos
immun
strategi
use
protein
antigen
nucleic
acidbas
antigen
potenti
associ
abil
chitosanbas
nanosystem
interact
mucos
tissu
specif
distribut
lymphat
system
accumul
inform
firmli
consolid
potenti
polysaccharid
biomateri
engin
new
vaccin
dextran
one
studi
drug
antigen
deliveri
polym
glucan
branch
obtain
bacteria
particularli
lactobacillu
leuconostoc
streptococcu
speci
raemdonck
et
al
nativ
bacteri
dextran
high
molecular
weight
water
solubl
use
characterist
pharmaceut
formul
purpos
also
structur
particularli
hydroxyl
group
allow
easi
function
chemic
modif
baldwin
kiick
final
biocompat
biodegrad
biomateri
togeth
high
avail
reduc
cost
product
make
attract
nanoengin
antigen
baldwin
kiick
raemdonck
et
al
import
mention
dextran
gra
statu
given
fda
use
human
long
time
mainli
plasma
volum
expand
antithrombot
agent
de
belder
sulfat
deriv
dextran
sulfat
ds
also
approv
fda
compon
apheresi
column
use
remov
low
densiti
lipoprotein
ldl
blood
wwwfdagov
sinc
immunomodul
properti
dextran
sulfat
potenti
use
adjuv
also
studi
overal
result
report
far
shown
abil
increas
antibodyand
cellmedi
immun
respons
anim
model
kerlin
watson
mccarthi
et
al
deriv
administ
ad
libitum
drink
water
wv
concentr
also
associ
strong
proinflammatori
effect
use
induc
inflammatori
diseas
coliti
mice
develop
anim
model
diseas
laroui
et
al
diethylaminoethyl
deae
dextran
anoth
deriv
adjuv
properti
studi
mostli
veterinari
vaccin
finnerti
et
al
nevertheless
mechan
action
deriv
still
well
understood
requir
research
cox
coulter
petrovski
cooper
case
chitosan
polysaccharid
dextran
explor
biomateri
nanoengin
protein
antigen
howev
case
despit
report
immunostimul
properti
activ
limit
studi
describ
parenter
vaccin
dextranbas
nanovaccin
dextran
nanoparticl
contain
ova
combin
lp
develop
administ
intraven
mice
shen
et
al
result
show
carrier
effici
intern
dc
induc
ovaspecif
tcell
prolifer
cell
well
stronger
immun
respons
comparison
control
empti
dextran
nanoparticl
lpsload
nanoparticl
ovaload
nanoparticl
dextran
nanoparticl
also
evalu
encapsul
immunostimul
molecul
cpg
poli
c
vitro
studi
show
upon
incub
macrophag
nanosystem
elicit
higher
product
cytokin
respect
free
molecul
demonstr
improv
adjuv
potenti
poli
c
cpg
incorpor
dextran
chitosanbas
nanosystem
recent
report
deliveri
capsid
protein
pertussi
toxoid
ptx
drogoz
et
al
sharma
et
al
anion
cation
chitosandextran
nanoparticl
prepar
modul
mass
ratio
polysaccharid
subsequ
load
subcutan
administr
healthi
mice
cation
anion
nanoparticl
render
igg
titr
compar
elicit
complet
freund
adjuv
cfa
drogoz
et
al
case
chitosandextran
nanoparticl
load
ptx
sharma
et
al
igg
respons
observ
subcutan
administr
mice
significantli
higher
one
elicit
alumadsorb
antigen
dextran
nanoparticl
also
prepar
combin
polyvinylalcohol
pva
encapsul
recombin
bacillu
anthraci
antigen
rpa
resiquimod
tlr
agonist
schulli
et
al
nanoparticl
subcutan
administ
mice
either
separ
combin
alumadsorb
antigen
first
observ
balanc
immun
respons
anim
receiv
resiquimod
inde
highest
level
igg
cytokin
product
observ
coadministr
resiquimodload
nanoparticl
combin
rpaload
nanoparticl
alumadsorb
rpa
combin
respons
anim
surviv
upon
three
challeng
pathogen
mucos
vaccin
dextranbas
nanovaccin
dextranbas
nanoparticl
bare
explor
intranas
vaccin
studi
iga
associ
dextran
nanoparticl
possibl
target
moieti
toward
cell
present
nasal
mucosa
singl
intranas
administr
fluorescentlabel
nanoparticl
healthi
mice
fluoresc
level
igadecor
dextran
nanoparticl
analys
confoc
microscopi
particularli
high
nasalassoci
lymphoid
tissu
nalt
cell
comparison
nasal
tissu
area
therefor
preliminari
data
suggest
potenti
nanoparticl
intranas
immun
despit
number
studi
report
use
chitosan
nanoparticl
dna
vaccin
studi
identifi
incorpor
dextran
nanostructur
applic
dextranbas
nanocarri
develop
genet
vaccin
overal
regardless
limit
number
studi
report
far
result
achiev
dextranbas
system
open
room
deeper
research
field
particularli
term
combin
polym
immunomodulatori
molecul
term
mannan
refer
storag
polysaccharid
abund
natur
consist
dmannos
monom
connect
bond
interest
polysaccharid
reli
abil
interact
ctype
lectin
group
receptor
express
apc
dc
macrophag
receptor
respons
recognit
differ
carbohydr
present
cell
wall
certain
pathogen
includ
mannos
receptor
mr
mannosebind
lectin
mbl
other
specif
dc
dcsign
apostolopoulo
et
al
recognit
process
describ
lead
endocytosi
phagocytosi
pathogen
major
import
innat
immun
process
elicit
complement
activ
trigger
inflamm
petersen
et
al
petrovski
cooper
moreov
interact
specif
dc
ctype
lectin
correl
dc
traffick
induct
humor
cellular
respons
apostolopoulo
et
al
target
nanovaccin
apc
use
approach
appli
differ
antigen
discuss
nevertheless
import
awar
limit
strategi
ubiquit
presenc
mannan
receptor
varieti
cell
includ
immun
cell
epitheli
cell
retina
mesangi
cell
kidney
muscular
trachea
cell
joshi
et
al
function
nanovaccin
mannos
residu
specif
target
protein
peptid
antigen
dc
macrophag
b
cell
evalu
murin
human
vitro
model
albarwani
et
al
ghotbi
et
al
thomannharwood
et
al
polymer
nanoparticl
base
copolym
pcl
polyethyleneglycol
peg
function
mannan
optimis
encapsul
human
basic
fibroblast
growth
factor
bfgf
cancer
immunotherapi
administ
healthi
mice
gou
et
al
fundament
role
mannan
evidenc
view
significantli
higher
igg
level
achiev
comparison
control
formul
ie
nontarget
nanoparticl
alumadsorb
antigen
moreov
immun
respons
bias
toward
pathway
shown
increas
level
particularli
import
confront
tumour
cell
anoth
studi
ovaload
mannandecor
plga
nanoparticl
also
found
elicit
higher
tcell
respons
compar
ovaload
nondecor
plga
nanoparticl
subcutan
administr
mice
final
vitro
macrophag
uptak
studi
perform
use
poli
methacrylatecomethacryl
acid
p
hemacomaa
nanogel
load
ova
reveal
high
intern
accompani
high
product
costimulatori
molecul
et
al
glucomannan
polym
link
dmannos
dglucos
also
studi
prepar
nanoparticl
alonsosand
et
al
hard
et
al
jain
et
al
b
bovin
serum
albumin
bsa
load
chitosan
nanoparticl
function
glucomannan
aim
achiev
improv
interact
macrophag
hard
et
al
upon
oral
administr
decor
nanoparticl
mice
immun
respons
term
igg
iga
titr
cytokin
product
significantli
higher
respect
nonfunction
nanoparticl
novel
approach
recent
explor
compris
modif
bilosom
nonion
surfactantbas
nanovesicl
contain
bile
salt
glucomannan
oral
antigen
deliveri
jain
et
al
b
bsa
tt
use
model
antigen
vitro
studi
show
glucomannanmodifi
bilosom
increas
uptak
macrophag
comparison
unmodifi
one
translat
stronger
system
mucos
immun
respons
follow
oral
administr
mice
nanoengin
nucleic
acid
mannan
mainli
achiev
synthesi
cation
deriv
mannan
lu
et
al
ruan
et
al
tang
et
al
tang
et
al
exampl
cation
mannanspermin
copolym
engin
complex
model
pdna
transfect
effici
test
panel
immortalis
cell
line
includ
macrophag
dendrit
cell
result
show
high
transfect
level
macrophag
associ
receptormedi
intern
mannan
complex
ruan
et
al
polym
conjug
mannan
oxid
reduc
form
polyllysin
pll
also
use
complex
pdna
encod
tumourassoci
antigen
anticanc
immunotherapi
upon
intraderm
immun
nanovaccin
lead
increas
cell
activ
antibodi
product
protect
anim
tumour
challeng
express
melanoma
cell
tang
et
al
addit
data
also
show
abil
nanovaccin
induc
dc
matur
depend
pathway
mediat
crosspresent
antigen
vivo
tang
et
al
mannanmodifi
cholesterol
also
synthes
use
prepar
function
cation
liposom
associ
plasmid
encod
melanomaassoci
antigen
pubm
lu
et
al
mice
immun
intraperiton
rout
prototyp
use
liposom
prepar
unmodifi
cholesterol
nake
plasmid
dna
control
result
evidenc
increas
gene
deliveri
splenic
macrophag
dc
achiev
via
mannos
receptor
higher
specif
ctl
activ
function
liposom
importantli
challeng
anim
inject
tumour
cell
group
treat
mannantarget
nanosystem
show
reject
inject
cell
suppress
growth
increas
surviv
gener
work
highlight
potenti
interest
mannan
target
agent
may
improv
abil
nanosystem
interact
immunocompet
cell
studi
necessari
order
assess
specif
benefit
strategi
group
differ
polym
glucos
vari
chain
length
well
number
posit
branch
polysaccharid
found
cell
wall
mani
organ
bacteria
yeast
even
speci
seawe
goodridg
et
al
glucan
known
baker
yeast
cerevisa
ganoderma
lucidum
mycelium
aureobasidium
pullulan
gra
statu
given
fda
use
food
ingredi
wwwfdagov
term
immunomodul
properti
research
done
noncellulos
glucan
curdlan
alcaligen
faecali
laminarin
laminaria
digitata
lentinan
lentinu
edod
pleuran
pleurotu
ostreatu
zymosan
saccharomyc
spp
goodridg
et
al
petrovski
cooper
role
beta
glucan
immun
respons
alreadi
explor
sever
decad
presenc
structur
differ
bacteria
fungi
make
easili
recogniz
prr
act
natur
pamp
soltanian
et
al
howev
adjuv
properti
one
specif
beta
glucan
gener
other
due
differ
paramet
size
branch
molecular
structur
adam
et
al
barsanti
et
al
sletmoen
stokk
soltanian
et
al
intervent
beta
glucan
immun
mainli
due
interact
specif
cell
receptor
pictur
fig
though
type
recognit
lead
similar
biolog
effect
worth
describ
detail
one
one
hand
complement
receptor
wide
present
myeloid
cell
macrophag
dc
natur
killer
nk
cell
first
receptor
describ
recognit
beta
glucan
though
biolog
effect
specif
interact
yet
fulli
understood
alreadi
shown
lead
complement
activ
subsequ
opsonis
follow
intern
structur
bose
et
al
goodridg
et
al
soltanian
et
al
hand
type
ii
transmembran
protein
present
myeloid
cell
studi
receptor
interact
beta
glucancontain
microorgan
synthet
particl
receptor
mediat
sever
process
reactiv
oxygen
speci
ro
cytokin
product
also
trigger
intern
pathogen
via
phagocytosi
goodridg
et
al
lipinski
et
al
mochizuki
sakurai
interact
led
use
beta
glucan
also
target
moieti
enhanc
specif
immun
respons
exampl
work
dube
et
al
chitosanco
plga
nanoparticl
function
euglena
gracili
target
result
increas
intracellular
deliveri
fig
schemat
represent
beta
glucan
recognit
immun
cell
receptor
two
main
beta
glucan
receptor
apc
macrophag
dendrit
cell
complement
receptor
interact
beta
glucancontain
fungi
bacteria
speci
well
synthet
glucan
nanoparticl
cell
may
lead
one
hand
complement
activ
particl
opsonis
phagocytosi
recognit
hand
secret
proinflammatori
cytokin
ro
togeth
enhanc
particl
phagocytosi
pathway
recognit
moreov
last
case
abil
trigger
action
helper
cell
adapt
immun
respons
process
may
also
relev
featur
beta
glucancontain
structur
recogn
encapsul
antituberculosi
drug
well
enhanc
proinflammatori
reaction
relev
product
reactiv
oxygen
nitrogen
speci
report
indic
properti
beta
glucan
attract
attent
research
explor
use
antigen
carrier
conjug
tetanu
toxoid
laminarin
laminaria
digitata
evalu
develop
vaccin
candida
albican
lipinski
et
al
new
conjug
antigen
abl
promot
receptorbas
dc
uptak
mediat
interact
laminarin
altogeth
result
enhanc
cytokin
product
strong
igg
antibodi
respons
intraperiton
subcutan
administr
mice
ifa
adjuv
lipinski
et
al
given
potenti
exhibit
beta
glucan
immunomodul
expect
increas
interest
use
develop
nanovaccin
howev
best
knowledg
one
exampl
relat
use
polysaccharid
isol
g
lucidum
mushroom
strong
immunomodul
properti
base
regul
nitric
oxid
cytokin
product
interact
tlr
prepar
nanos
complex
poli
c
tincer
et
al
igg
respons
observ
intraperiton
administr
ovaload
nanoparticl
mice
higher
elicit
control
ie
physic
mixtur
ova
poli
c
ova
posit
vivo
respons
correl
increas
cytokin
product
incub
nanoparticl
macrophag
studi
also
highlight
potenti
beta
glucan
deliveri
nucleic
acid
antigen
synthet
cation
glucan
obtain
g
lucidum
report
effici
associ
model
pdna
encod
luciferas
achiev
adequ
transfect
human
embryon
kidney
transform
cell
wang
et
al
anoth
exampl
one
make
use
schizophyllan
spg
complex
oligonucleotid
odn
deliveri
macrophag
therapeut
target
induc
hepat
damag
upon
intraperiton
administr
either
spgodn
complex
compon
individu
mice
bear
lpsinduc
hepat
damag
odn
effici
deliv
apc
target
exhibit
encourag
therapeut
effect
mochizuki
sakurai
overal
beta
glucan
present
intrins
properti
increas
interest
use
vaccin
develop
demonstr
review
nevertheless
result
achiev
polym
still
preliminari
particularli
case
develop
antigen
nanocarri
real
potenti
beta
glucan
field
yet
demonstr
throughout
past
decad
sever
innov
biolog
techniqu
appli
design
develop
safer
effect
vaccin
howev
need
potent
adjuv
enhanc
immun
respons
elicit
modern
antigen
also
grown
nowaday
import
research
field
within
frame
nanotechnolog
play
increasingli
import
role
given
appropri
featur
offer
nanocarri
administr
antigen
includ
particul
natur
control
particl
size
abil
protect
antigen
degrad
deliv
control
manner
possibl
overcom
mucos
rout
abil
includ
costimulatori
molecul
may
enhanc
global
adjuv
effect
nanocarri
context
use
polysaccharid
develop
novel
nanovaccin
repres
crucial
step
due
interest
intrins
properti
chitosan
mucoadhes
effect
activ
macrophag
particularli
relev
vaccin
deliveri
polysaccharid
studi
one
develop
nanovaccin
nevertheless
use
polysaccharid
field
slowli
grow
even
though
mani
bare
known
nanovaccin
compon
recogn
immunomodul
properti
open
room
research
progress
particular
area
global
recent
work
nanovaccin
develop
demonstr
potenti
strategi
confront
current
barrier
vaccin
nevertheless
import
take
consider
combin
biomateri
use
specif
formul
chosen
antigen
rout
administr
nanovaccin
critic
factor
influenc
final
outcom
vaccin
strategi
use
biomateri
especi
natur
polym
prepar
antigen
deliveri
system
one
main
tendenc
field
vaccin
howev
natur
origin
materi
often
respons
high
variabl
characterist
specif
polym
therefor
may
lead
variabl
even
controversi
result
term
adjuv
activ
also
challeng
term
progress
innov
vaccin
formul
toward
clinic
develop
commerci
therefor
expect
next
year
bring
deeper
knowledg
term
mechan
action
polym
might
drive
path
ration
design
polysaccharidebas
nanoparticl
adjuv
particular
issu
achiev
thermal
stabl
formul
avoid
cold
chain
vaccin
storag
might
one
challeng
nanovaccin
like
face
next
step
way
final
optim
prepar
method
use
nanovaccin
develop
order
adequ
manufactur
industri
level
major
topic
address
near
futur
field
combin
accumul
knowledg
could
necessari
drive
forc
take
polysaccharidebas
nanovaccin
toward
next
level
ultim
achiev
clinic
use
